Navigation Links
Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
Date:11/13/2011

SAN FRANCISCO Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents.

The experimental agent, PF-03446962, targets activin receptor-like kinase 1 (ALK-1), which is part of the transforming growth factor (TGF) superfamily of receptors that potentially regulate cell growth and differentiation. Known as a tumor suppressor, TGF can conversely promote invasion and metastasis during the later stages of cancer progression, said Filippo de Braud, M.D., who was director of new drugs at the European Institute of Oncology when the study was conducted and is now chief of the Medical Oncology Department at the National Tumor Institute in Milan, Italy.

Tumor cells frequently lose the growth inhibitory response to TGF, which makes it a prime target for cancer treatment, he said. PF-03446962, a fully humanized monoclonal antibody, specifically inhibits the activity of ALK-1, which the researchers said is in part regulated by vascular endothelial growth factor (VEGF), the protein that activates angiogenesis and other proangiogenic factors. Shutting down ALK-1 inhibits the VEGF pathway in a manner different from other antiangiogenic treatments now on the market, de Braud said.

Researchers tested PF-03446962 in a phase 1 clinical trial, which demonstrated that the agent exerted anticancer activity in tumors already resistant to VEGF treatment.

De Braud and his colleagues tested eight different doses of PF-03446962 in 44 patients with solid tumors. Results showed a partial response in three patients and stable disease lasting at least four months in seven patients. Most of the patients who benefitted had previously been treated with prior antiangiogenic therapy for lung, renal or liver cancer. Some of these patients did not achieve remission with previous antiangiogenic therapy, "suggesting that ALK-1 can operate as an escape mechanism to VEGF," de Braud said.

The two patients with the longest response (stable disease for about a year) had been diagnosed with adrenocortical cancer and mesothelioma.

The researchers noted that three patients developed telangiectasia, which is dilation of blood vessels near the skin. This disorder is known to be caused by a mutation in the ALK-1 gene, and development of this mild side effect in these patients demonstrates PF-03446962 is affecting ALK-1 function.

"Based on this clinical activity, anti-ALK-1 may be a promising novel strategy to help patients who have failed previous VEGF therapy," de Braud said. The agent might be used on its own or in combination with current antiangiogenic therapy to strengthen inhibition of the VEGF pathway.

Toxicities seen in the phase 1 trial were manageable, a finding that demonstrates that the agent is safe to use, he said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Benefit of novel drug in breast cancer seen in blood within weeks
2. Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
3. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
4. Novel technique uses RNA interference to block inflammation
5. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
6. Novel drug combination offers therapeutic promise for hard-to-treat cancers
7. Novel approach scores first success against elusive cancer gene
8. Novel method for increasing antibiotic yields
9. Tropical coral could be used to create novel sunscreens for human use, say scientists
10. A novel mechanism that regulates pro-inflammatory cells is identified
11. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... MENLO PARK, Calif. , Dec. 6, 2016 ... of up to $150 million from the National ... Infectious Diseases and the Division of AIDS (NIAID-DAIDS) ... microbicides and other non-vaccine pre-exposure (PreP) agents. Under ... suite of preclinical product development services for candidate ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... integration, and building management solutions headquartered in Aurora, Ohio, announced the opening of ... Springs, North Carolina, the newly constructed facility is home to 200 employees focused ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... and their discovery using various -omics technologies such as proteomics and ... and new tests are also based on biomarker. Currently ...
(Date:12/5/2016)... 2016 According to the ... Products (Consumable, Instruments, Automated Cell Expansion System), Cells ... Cell Research, Cancer, and Cell-Based Research), End-users (Biopharmaceutical ... Global Revenue, Trends, Growth, Share, Size and Forecast ... global cell expansion market is expected to reach ...
Breaking Biology Technology: